O-MAX Chemotherapy: High Activity in Metastatic Esophagogastric Adenocarcinoma and Possible Relation to Subclinical Hemolysis

Publisher： Karger

E-ISSN： 1423-0232|87|6|371-380

ISSN： 0030-2414

Source： Oncology, Vol.87, Iss.6, 2014-09, pp. : 371-380

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report

By  

Case Reports in Oncology, Vol. 8, Iss. 2, 2015-08 ,pp. : 339-344

Karger

Access to resources Recommend Favorite

Prognostic Factors in Patients with Metastatic Pancreatic Adenocarcinoma Receiving Systemic Chemotherapy

By  

Oncology, Vol. 59, Iss. 4, 2000-11 ,pp. : 296-301

Karger

Access to resources Recommend Favorite

Perioperative Chemotherapy in Elderly Patients with Locally Advanced Adenocarcinoma of the Stomach and the Esophagogastric Junction: A Retrospective Cohort Analysis of Toxicity and Efficacy at the National Center for Tumor Diseases, Heidelberg

By  

Oncology, Vol. 92, Iss. 5, 2017-03 ,pp. : 291-298

Karger

Access to resources Recommend Favorite

Distribution of High Chromogranin A Serum Levels in Patients with Nonmetastatic and Metastatic Prostate Adenocarcinoma

By  

Urologia Internationalis, Vol. 82, Iss. 2, 2009-03 ,pp. : 147-151

Karger

Access to resources Recommend Favorite

5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

By  

Oncology, Vol. 80, Iss. 5-6, 2011-07 ,pp. : 301-306

Karger

Access to resources Recommend Favorite